

## FY20 FULL YEAR RESULTS

---

### HIGHLIGHTS:

- Sales revenue \$1.2m, up 77%
  - Other income \$2.1m, up 149%
  - Operating costs \$16.1m, up 127%
  - Cash reserves \$8.4m, up 173%
  - Loss after tax \$21.97m (including non-cash interest expense of \$7.7m), up 239%
  - FDA 510(k) clearance received for 4DMedical's first Software-as-a-Service (SaaS) product – XV LVAS
  - Successful \$55.8m IPO on the ASX in August 2020 (FY21) ensures that 4DMedical is fully funded to execute its growth strategy and accelerate the roll out of XV LVAS in the U.S.
- 

**28 August 2020:** 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”), a medical technology company focused on commercialising its patented respiratory imaging technology, today announces its full year results for the financial year ended 30 June 2020 (FY20).

During the period, operating revenue and other income increased by 117% to \$3.4m with \$1.2m in reported sales of preclinical hardware and SaaS revenue.

4DMedical reported a net loss after tax of \$21.97m for the period, which includes a non-cash interest expense of \$7.7m relating to the convertible notes issued in December 2019. These convertible notes and associated accrued interest were converted into equity on 7 August 2020.

The Company's cash reserves at 30 June 2020 were \$8.4m, up 173% from 30 June 2019, which excludes the capital raised from its initial public offering (IPO) completed in August 2020 after the FY20 period.

The IPO successfully raised \$55.8m, including \$50.0m of new capital, and was strongly supported by a wide range of institutional and retail investors, including both new and existing shareholders.

As set out in 4DMedical's prospectus, the proceeds from the IPO will be used to execute 4DMedical's growth strategy, which is predominantly focused on increasing sales and marketing capabilities in the U.S., executing its clinical trial strategy to drive market penetration, and additional investment into research and development of its product portfolio.

In May 2020, 4DMedical received confirmation that its Lung Ventilation Analysis Software (XV LVAS) obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This regulatory clearance represents a significant milestone as it validates over 15 years of research and development and allows the Company to commence selling XV LVAS to hospitals and clinics in the U.S.

### Andreas Fouras, Founder & CEO of 4DMedical said:

“We are extremely pleased to announce our FY20 results on the back of achieving some significant milestones. The combination of our FDA 510(k) clearance and successful IPO allows 4DMedical to begin leveraging demand for innovative lung diagnostics and begin commercialising our SaaS products in the U.S.

The next 12 months will be an exciting period for 4DMedical as we begin to deliver on our mission to improve the respiratory health of patients globally.

We look forward to providing further detail on the business' operations during the financial year within the Company's 2020 Annual Report."

## ENDS

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, CEO.

### Contacts:

#### *Corporate*

Charlene Stahr

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### *Investor*

Simon Hinsley

+ 61 401 809 653

[shinsley@4dmedical.com](mailto:shinsley@4dmedical.com)

#### *Media*

Matthew Wright

+ 61 451 896 420

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2013 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a \$30 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.